Point72 Asset Management’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-166,418
Closed -$14.5M 2061
2024
Q4
$14.5M Buy
+166,418
New +$15.2M 0.03% 568
2024
Q3
Sell
-501,581
Closed -$54.1M 1996
2024
Q2
$54.1M Buy
501,581
+221,813
+79% +$22.2M 0.14% 200
2024
Q1
$26.5M Buy
279,768
+239,333
+592% +$20.5M 0.06% 361
2023
Q4
$3.73M Sell
40,435
-555,365
-93% -$36M 0.01% 1021
2023
Q3
$29.9M Buy
+595,800
New +$31.8M 0.09% 303
2022
Q3
Sell
-172,482
Closed -$8.71M 1419
2022
Q2
$8.71M Buy
+172,482
New +$10.1M 0.04% 544
2021
Q4
Sell
-418,200
Closed -$43M 1101
2021
Q3
$43M Buy
418,200
+157,356
+60% +$14.7M 0.19% 134
2021
Q2
$22.9M Buy
+260,844
New +$23.9M 0.1% 255
2020
Q1
Sell
-209,729
Closed -$16.8M 789
2019
Q4
$16.8M Buy
+209,729
New +$15.7M 0.09% 284
2018
Q2
Sell
-279,957
Closed -$25.7M 981
2018
Q1
$25.7M Sell
279,957
-18,052
-6% -$1.56M 0.11% 249
2017
Q4
$22.5M Sell
298,009
-18,191
-6% -$1.28M 0.1% 279
2017
Q3
$22M Sell
316,200
-81,908
-21% -$4.38M 0.1% 247
2017
Q2
$20.2M Buy
398,108
+295,108
+287% +$12.5M 0.11% 245
2017
Q1
$4.12M Buy
+103,000
New +$3.69M 0.02% 574

Other funds holding BPMC

Point72 Asset Management's BPMC Position: Q1 2025 in Review

Point72 Asset Management sold out of Blueprint Medicines (BPMC) in Q1 2025, closing a stake of 166,418 shares — an estimated $14.5M sold.

Point72 Asset Management first reported a position in BPMC in Q1 2017 and held it in 14 quarters. The position peaked at $54.1M in Q2 2024. 352 funds tracked by Wall St. Rank hold BPMC as of Q1 2025.

  • Point72 Asset Management reported no remaining Blueprint Medicines position as of Q1 2025 after selling out during the quarter.
  • Point72 Asset Management sold 166,418 Blueprint Medicines shares in Q1 2025, an estimated $14.5M.
  • Point72 Asset Management first reported a position in Blueprint Medicines in Q1 2017 and held it in 14 quarters.
  • Point72 Asset Management's Blueprint Medicines position peaked at $54.1M in Q2 2024.
  • 352 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2025.

Based on Point72 Asset Management's 13F filing for Q1 2025, filed 15 May 2025.